NXGN - NextGen trades high on Q4 prelim results raises FY21 guidance

NextGen Healthcare (NXGN) reported prelim Q3 results wherein on a GAAP basis revenue is seen between $140 and $142M vs. $137.7M in year ago quarter.Diluted net income per share is expected to be between ($0.01) and $0.03 vs. $0.07 in year ago quarter.Non-GAAP diluted EPS is seen between $0.24 and $0.26 compared to $0.23 in year ago quarter.For FY21, the company raised its revenue guidance to $547 and $555M from its earlier range of $535 and $551M; non-GAAP EPS to be between $0.92 and $0.98 from the prior range of $0.83 and $0.93.Shares +2.6% premarket.

For further details see:

NextGen trades high on Q4 prelim results, raises FY21 guidance